New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The ...

Panelists discuss the complexities of managing metastatic melanoma with asymptomatic brain metastases in patients with good performance status, emphasizing challenges posed by treatment resistance and ...

Panelists discuss the importance of effective communication and multidisciplinary collaboration in managing immunotherapy toxicities and ensuring seamless patient care, while highlighting promising ...

Experienced oncology nurses and APPs can help nurses newer to the field understand who is more at risk of opioid addiction, ...

Panelists discuss how the unprecedented 5-year progression-free survival benefit (60% vs 8%) demonstrated in the CROWN trial ...

Explore essential mental health support strategies for older adults with cancer, addressing grief, community resources, and ...

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according ...

Panelists discuss that talquetamab dose modifications are guided primarily by patient symptoms and adverse effects, with ...

Establishing a routine early in treatment helps proactively manage adverse effects associated with CDK4/6 inhibitors, says ...

ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become ...